DOCSLIB.ORG

SAC 2014 Celebration of Science Book

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SAC 2014 Celebration of Science Book Fostering Innovation at MGH Poster Session Abstracts 67th Annual Meeting of the MGH Scientific Advisory Committee Celebration of Science The MGH Research Institute: Meeting the Challenges that Lie Ahead April 2 & 3, 2014 Simches Auditorium 185 Cambridge Street, 3rd Floor Management Management ECOR Administrative Offices | 50 Staniford Street, 10th Floor | Boston, MA 02114 | [email protected] Fostering Mainstay Mainstay Innovation of MGH of MGH at MGH Management Innovation Management Innovation Welcome elcome to the 67th Annual Meeting of the MGH Scientific Advisory Committee (SAC) on April 2nd and 3rd, 2014. Dr. Richard Lifton has graciously agreed to W chair our SAC meeting again this year. As in past years, we will begin our two-day SAC meeting with a Celebration of Science at MGH. Our poster session begins at 11:00 am on Wednesday, April 2, followed by an afternoon Research Symposium from 2:00 pm to 5:00 pm. The outstanding MGH researchers who will be presenting their work in our Symposium this year are the 2014 Howard Goodman Award recipient Filip Swirski, PhD and the 2014 Martin Basic and Clinical Research Prize recipients, Jayaraj Rajagopal, MD, and Stephanie Seminara, MD. We are honored to have as our keynote speaker, Richard O. Hynes, PhD, from MIT. We will close the first day with a Reception for invited guests at the Russell Museum. On Thursday, April 3, Dr. Kingston will open the SAC meeting with an ECOR Report. After this report, Anne Klibanski, MD, Partners Chief Academic Officer, will give a presentation on the Integration of MGH Research to the Partners Enterprise. We will next turn our attention to department presentations by the Chiefs of Neurology (Merit E. Cudkowicz, MD, MSc) and Surgery (Keith Lillemoe, MD), who will describe some of the remarkable research being conducted across MGH. Over the past year and a half, the hospital has conducted a rigorous Strategic Planning Initiative. Harry W. Orf, PhD, Senior VP for Research will close the morning session with an overview of the Research Strategic Plan with his presentation on the MGH Research Institute. Our afternoon sessions will include three focused discussions on the main components of the Research Institute. The initiatives we will explore are: 1. Clinical Research Reorganization—presented by Jerrold F. Rosenbaum, MD 2. Translational Research Center—presented by Mason W. Freeman, MD 3. Life Registry—presented by Susan A. Slaugenhaupt, PhD Experience has reaffirmed that we get the most helpful advice and perspective from SAC via open discussion of key issues. This year we have made a concerted effort to shorten presentations to allow more time for discussion with the SAC members. Also on Thursday, SAC members will again have the opportunity to meet with small groups of MGH investigators in unstructured, informal conversations during breakfast. To maximize the time for discussion during the day, the annual MGH Research Administration Executive Report and Financials for FY13 will be provided in these printed materials in advance of the meeting. Dr. Kingston plans to highlight some of this information in his annual ECOR Report and there will be an opportunity for SAC members to ask questions about the written report. We look forward to an engaging and stimulating two days of discussion and appreciate your participation. Peter L. Slavin, MD Robert E. Kingston, PhD Harry W. Orf, PhD President Chair, EXecUtive Committee Senior Vice President ON Research for Research SAC 2014 Executive Committee on RESEARCH 1 Agenda: Day One, Wednesday, April 2, 2014 Annual Celebration of Science at MGH 11:00 am–1:45 pm SAC 2014 Poster Session (light lunch available) Wyndham,15th Floor 2:00–5:00 pm Scientific Presentations Simches 3.110 WELCOME Peter L. Slavin, MD, President, Massachusetts General Hospital OpENING COMMENTS AND INTRODUCTIONS Robert E. Kingston, PhD, Chair, Executive Committee On Research (ECOR) 2014 MGH RESEARCH SCHOLARS Robert E. Kingston, PhD 2:15–2:45 pm 2014 Martin Prize for Basic Research Dedifferentiation of Committed Epithelial Cells Into Stem Cells in Vivo Jayaraj Rajagopal, MD 2:45–3:15 pm 2014 Martin Prize for Clinical Research Ataxia, Dementia, and Hypogonadotropism Caused by Disordered Ubiquitination Stephanie B. Seminara, MD 3:15–3:45 pm 2014 Goodman Award The Role of IRA B Cells in Sepsis Filip K. Swirski, PhD 3:45–4:00 pm Break 4:00–5:00 pm Keynote INTRODUCTION Peter L. Slavin, MD Platelets and Extracellular Matrix—Under-appreciated Key Players in Metastasis Richard O. Hynes, PhD, Daniel K. Ludwig Professor for Cancer Research Investigator, Howard Hughes Medical Institute Massachusetts Institute of Technology 5:00–7:00 pm Reception (for invited guests) Russell Museum 2 Executive Committee on RESEARCH SAC 2014 Agenda: Day Two, Thursday, April 3, 2014 Annual Celebration of Science at MGH 8:00–9:00 am BREAKFAST SERI 2nd Floor SAC Members with small groups of MGH Faculty 9:00–9:15 am WELCOME AND OpENING COMMENTS Simches 3.110 Peter L. Slavin, MD, President, Massachusetts General Hospital 9:15–9:40 am ECOR REPORT 2013 Robert E. Kingston, PhD, Chair, Executive Committee On Research (ECOR) 9:40–10:00 am INTEGRATION OF MGH RESEARCH TO THE PARTNERS ENTERPRISE Anne Klibanski, MD, Partners Chief Academic Officer 10:00–11:30 am DEPARTMENT REPORTS 10:00–10:40 am Neurology, Merit E. Cudkowicz, MD, MSc 10:40–10:50 am Break 10:50–11:30 am Surgery, Keith D. Lillemoe, MD The MGH Research Institute: Meeting the Challenges that Lie Ahead 11:30 am–12:00 pm OVERALL ORGANIZATION: THE RESEARCH INSTITUTE Harry W. Orf, PhD, Sr. Vice President for Research 12:00–1:30 pm Lunch SERI 2nd Floor SAC Members with ECOR and Hospital Leadership Simches 3.120 ECOR Members & Speakers 1:30–1:40pm CLINICAL RESEARCH REORGANIZATION, Jerrold F. Rosenbaum, MD Simches 3.110 1:40–2:00 pm Discussion 2:00–2:10 pm TRANSLATIONAL RESEARCH CENTER, Mason W. Freeman, MD 2:10–2:30 pm Discussion 2:30–2:40 pm LIFE REGISTRY, Susan A. Slaugenhaupt, PhD 2:40–3:00 pm Discussion 3:00–3:15 pm Break 3:15–3:45 pm EXECUTIVE SEssION (SAC members only) Simches 3.120 3:45–4:15 pm DEBRIEFING (SAC members and MGH Leadership) Simches 3.120 SAC 2014 Executive Committee on RESEARCH 3 Goodman & Martin Award Winners Howard M. Goodman Fellowship 2014 The Fellowship honors Howard M. Goodman, founder of the MGH Department of Molecular Biology in 1982 and Chief of that Department until 2004. Dr. Goodman’s guiding principle was that great science should not be encumbered by the continual need to convince the world concerning the merit of an individual scientific vision. He believed in choosing scientists of demonstrated excellence and giving them the resources to pursue their goals with vigor, a model that was resoundingly successful. Each year a Goodman Fellow is chosen from the MGH community to honor that legacy and to support the pursuit of excellence by young scientists of uncommon passion and ability. The Role of IRA B Cells in Sepsis Filip Swirski, PhD Assistant Professor Center for Systems Biology Martin Research Prize 2014 for Basic and Clinical Research The Martin Research Prizes were established to honor Joseph B. Martin, MD, PhD, who was Dean of Harvard Medical School from July 1997 to July 2007. Prior to becoming Dean, Dr. Martin was Chief of the Neurology Service at MGH. Each year, ECOR awards two $100,000 Martin Research Prizes to recognize outstanding research papers published by MGH investigators in Basic research and Clinical research. BASIC RESEARCH Dedifferentiation of Committed Epithelial Cells Into Stem Cells in Vivo Jayaraj Rajagopal, MD Assistant Professor Center for Regenerative Medicine CLINICAL RESEARCH Ataxia, Dementia, and Hypogonadotropism Caused by Disordered Ubiquitination Stephanie Seminara, MD Associate Professor Reproductive Endocrine 4 Executive Committee on RESEARCH SAC 2014 Keynote Speakers Profile:Keynote MGH SpeakerScholars Richard O. Hynes, PhD, FRS Richard Hynes was educated at Cambridge University (BA, MA) and MIT (PhD). He is the Daniel K. Ludwig Professor for Cancer Research at the Koch Institute and Department of Biology at MIT, Investigator of the Howard Hughes Medical Institute and Senior Associate Member of the Broad Institute. He was formerly Associate Head and then Head of the Biology Department and was Director of the MIT Cancer Center for 10 years. He is a Fellow of the Royal Society (FRS) of London and a Member of the US National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences. Dr. Hynes was born in Nairobi, Kenya and grew up in Liverpool, England. He did his undergraduate work at Trinity College in Cambridge, UK, and his PhD at MIT with Paul Gross, separating different cell types from early sea urchin embryos and studying the complexity of their RNA sequences. He then returned to the UK as a postdoctoral fellow at the Imperial Cancer Research Fund in London. By investigating the molecular changes on cell surfaces that distinguish cancer cells from normal cells, he discovered fibronectin, a cell adhesion protein present on normal cells that was noticeably absent on cancer cells. Dr. Hynes then went back to become an Assistant Professor in the Cancer Center and Biology Department at MIT in 1975, where he continued to work out the biology of fibronectin, the discovery of which set into motion a string of studies that has helped to establish cell adhesion as its own field of investigation. He showed that the extracellular matrix was connected across the membrane to the actin cytoskeleton. Dr. Hynes’s studies also contributed to the discovery and subsequent cloning of integrins, a family of protein receptors that gives cells their stickiness by binding with fibronectin and other cell adhesion molecules.
Load more

Recommended publications
  • ANNUAL REVIEW 1 October 2005–30 September
    WELLCOME TRUST ANNUAL REVIEW 1 October 2005–30 September 2006 ANNUAL REVIEW 2006 The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. It funds innovative biomedical research, in the UK and internationally, spending around £500 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing. www.wellcome.ac.uk THE WELLCOME TRUST The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. 123 CONTENTS BOARD OF GOVERNORS 2 Director’s statement William Castell 4 Advancing knowledge Chairman 16 Using knowledge Martin Bobrow Deputy Chairman 24 Engaging society Adrian Bird 30 Developing people Leszek Borysiewicz 36 Facilitating research Patricia Hodgson 40 Developing our organisation Richard Hynes 41 Wellcome Trust 2005/06 Ronald Plasterk 42 Financial summary 2005/06 Alastair Ross Goobey 44 Funding developments 2005/06 Peter Smith 46 Streams funding 2005/06 Jean Thomas 48 Technology Transfer Edward Walker-Arnott 49 Wellcome Trust Genome Campus As at January 2007 50 Public Engagement 51 Library and information resources 52 Advisory committees Images 1 Surface of the gut. 3 Zebrafish. 5 Cells in a developing This Annual Review covers the 2 Young children in 4 A scene from Y fruit fly. Wellcome Trust’s financial year, from Kenya. Touring’s Every Breath. 6 Data management at the Sanger Institute. 1 October 2005 to 30 September 2006. CONTENTS 1 45 6 EXECUTIVE BOARD MAKING A DIFFERENCE Developing people: To foster a Mark Walport The Wellcome Trust’s mission is research community and individual Director to foster and promote research with researchers who can contribute to the advancement and use of knowledge Ted Bianco the aim of improving human and Director of Technology Transfer animal health.
    [Show full text]
  • Vol 9 No 1 Spring
    A PUBLICATION OF THE AMERICAN SOCIETY FOR MATRIX BIOLOGY SPRING 2010, VOLUME 9, NO. 1 President’s Letter Expanding the Society’s Value to You and Your Role in the Society Since its inception in 2001, the principal function of the ASMB has been to organize the OFFICERS biennial meeting. The value of this meeting to our members cannot be understated. The ASMB meeting has emerged as the matrix-centric President: meeting in North America, and it provides an William Parks (2010) open venue for students, postdocs, fellows, and junior faculty to present their work and to inter- act with established investigators. Speaking for Vice Pres/President Elect myself, I very much look forward to the ASMB Jean Schwarzbauer (2010) meeting, not only because I get to see many Bill Parks friends, but also to hear a lot of incredibly good science. This year’s meeting will be no excep- Past President: tion and promises to be truly outstanding. I applaud Jean Schwarzbauer and the Renato Iozzo (2010) rest of the Program Committee for putting together an exciting meeting loaded with interesting topics and great speakers (please check out the program here). By organizing the meeting, ASMB provides value to you, the membership, but I Secretary/Treasurer think we–the Society–should always be looking to do more; that is, to provide more Joanne Murphy-Ullrich (2011) bang for your dues buck. For this year’s meeting, we have expanded the Travel Awards that will be given to trainees in recognition of outstanding research, and we recently established merit-based Minority Scholarships that will be awarded to eli- Council Members gible students and postdocs.
    [Show full text]
  • Hhmi Bulletin 3 4 Hhmi Club
    HHMI BULLETIN 4000 Jones Bridge Road • Chevy Chase, Maryland 20815-6789 Howard Hughes Medical Institute www.hhmi.org One Lump or Two? in this issue Once again, those fast-growing yeast find a way to turn a The Silicon Marvel long-held theory on its head. This time, it’s about prions, • Prions for Good which aren’t as universally nasty as once suspected. Some may actually help organisms evolve. The yeast colony shown here www.hhmi.org A Kaleidoscopic View contains a protein in its prion form. Because the prion, known as PSI+, is self-replicating and forms fibrous amyloids, the yeast look lumpy and bumpy—strikingly different from normally smooth yeast. Susan Lindquist’s group has found 19 yeast proteins that can switch back and forth between a normal and a prion version. The prions are thought to help the yeast adapt to changing conditions (see “A Silver Lining,” page 22). LIGHT MOVES v ol. 23 Heather True / Lindquist lab /no. 02 O b s e r v a t i O n s 16 Secret Agent MAn Skin cells do more than just cover our bodies. As a neurology resident, Stanley Prusiner saw Creutzfeldt–Jakob agent began to emerge. These data established, for the first time, that Keratinocytes, for example, anchor immune cells disease kill a patient in a matter of months. Researchers knew the rare a particular macromolecule was required for infectivity and that this within the epidermis, move and proliferate during neurodegenerative disease and scrapie, a similar disease in sheep, macromolecule was a protein …. wound healing, and even secrete inhibitory molecules were infectious but not as a result of a typical virus.
    [Show full text]
  • Summarised Financial Statements 2012
    Summarised Financial Statements 2012 Contents Chairman’s Statement 02 02 Summary Trustee’s Report 04 04 Vision and Objects, Mission, Focus Areas 04 and Challenges Financial Review 06 Extracts from the Review of Investment Activities 08 Independent Auditors’ Report 10 10 Consolidated Statement of Financial Activities 11 Consolidated Balance Sheet 12 Consolidated Cash Flow Statement 13 Grants Awarded 14 Reference and Administrative Details 16 Chairman’s Statement Sustained investment in research can bring real benefits or Medicine which was shared by a dozens of genomes every day. Their former Governor of the Trust, work is driving the first wave of Professor Sir John Gurdon. His work stratified medicine, improving cancer showed that mature cells had the therapy for patients by examining the potential to be reprogrammed into genetics of individual tumours, and stem cells. Subsequent decades of revealing the genetic basis of the way investment in stem cell research have specific cancers respond to different brought us ever closer to realising the drugs. promise of stem cell therapies. At the same time, ever-improving We saw again this year how sustained technology is giving us an advantage investment in research can bring real against infectious diseases. A study benefits. Genetics has been one of the published this summer demonstrated Trust’s most focused areas of funding how modern genome sequencing Summary of Chairman’s since the mid-1990s. First, we sought could track methicillin-resistant Statement to decode the human genome; then Staphylococcus aureus (MRSA). we had to find ways to apply that Retrospective analysis of samples • We committed £701 million in grant knowledge.
    [Show full text]
  • February 7, 2007 (Download PDF)
    Volume 51 – Number 16 Wednesday – February 7, 2007 TechTalk S ERVING T HE M I T C OMMUNITY Reactivated gene shrinks tumors, MIT study finds Anne Trafton cancer treatments,” said David Kirsch of known whether such activity would actu- properly, it activates DNA repair mecha- News Office MIT’s Center for Cancer Research and ally reverse tumor growth in primary nisms and prevents cells with damaged Harvard Medical School, one of the lead tumors. DNA from dividing. If DNA damage is co-authors of the paper. The new MIT study shows that re-acti- irreparable, p53 induces the cell to destroy Many cancers arise due to defects in The study appeared in the Jan. 25 vating p53 in mouse tumors dramatically itself by undergoing apoptosis, or pro- genes that normally suppress tumor issue of Nature. It was conducted in the reduces the size of the tumors, in some grammed cell death. growth. Now, for the first time, MIT laboratory of Tyler Jacks, director of the cases by 100 percent. When p53 is turned off by mutation researchers have shown that re-activat- Center for Cancer Research, the David H. “This study provides critical genetic or deletion, cells are much more likely ing one of those genes in mice can cause Koch Professor of Biology and a Howard evidence that continuous repression of a to become cancerous, because they will tumors to shrink or disappear. Hughes Medical Institute investigator. tumor suppressor gene is required for a divide uncontrollably even when DNA is The study offers evidence that the P53 has long been known to play a tumor to survive,” said Andrea Ventura, an damaged.
    [Show full text]
  • 2019: the Year in Experimental Medicine Why Submit to Jem?
    2019: THE YEAR IN EXPERIMENTAL MEDICINE WHY SUBMIT TO JEM? FORMAT NEUTRAL You may submit your papers in ANY format. 92% OF INVITED REVISIONS ARE ACCEPTED TRANSFER POLICY We welcome submissions that include reviewer comments from another journal. You may also request manuscript transfer between Rockefeller University Press journals, and we can confidentially send reviewer reports and identities to another journal beyond RUP. INITIAL DECISION IN 6 DAYS FAIR AND FAST We limit rounds of revision, and we strive to provide clear, detailed decisions that illustrate what is expected in the revisions. Articles appear online one to two days after author proofs are returned. TIME IN PEER REVIEW 38 DAYS OPEN ACCESS OPTIONS Our options include Immediate Open Access (CC-BY) and open access six months after publication (CC-BY-NC-SA). *Median 2019 An Editorial Process Guided by Your Community At JEM, all editorial decisions on research manuscripts are made through collaborative consultation between professional scientific editors and the academic editorial board. Submission or transfer Academic and scientific If appropriate, sent Academic and scientific Informed decisions editors review to Peer Review editors review comments sent to authors Revised manuscript Academic and scientific 92% of invited Published online Circulated via alerts and submission and rereview editors review revisions accepted* 1-2 days after author social media to readers proofs returned around the world 2019: THE YEAR IN EXPERIMENTAL MEDICINE t the beginning of 2020, the start of a new decade, the Journal of Experimental Medicine (JEM) is proud to present our annual Year in Experimental Medicine collection to highlight some of the articles that were of greatest interest to our readers last year.
    [Show full text]
  • MSU Commencement Ceremonies Fall 2020
    COMMENCEMENT CEREMONIES FALL 2020 “Go forth with Spartan pride and confdence, and never lose the love for learning and the drive to make a diference that brought you to MSU.” Samuel L. Stanley Jr., M.D. President Michigan State University Photo above: an MSU entrance marker of brick and limestone, displaying our proud history as the nation’s pioneer land-grant university. On this—and other markers—is a band of alternating samara and acorns derived from maple and oak trees commonly found on campus. This pattern is repeated on the University Mace (see page 10). Inside Cover: Pattern of alternating samara and acorns. Michigan State University photos provided by University Communications. ENVIRONMENTAL TABLE OF CONTENTS STEWARDSHIP Mock Diplomas and the COMMENCEMENT Commencement Program Booklet 3 Virtual Commencement Ceremonies Commencement mock diplomas, 4 The Michigan State University Board of Trustees which are presented to degree 5 Michigan State University Mission Statement candidates at their commencement 6–8 Congratulatory Letters from the President, Provost, and Executive Vice President ceremonies, are 30% post-consumer 9 Michigan State University recycled content. The Commencement 10 Ceremony Lyrics program booklet is 100% post- 11 University Mace consumer recycled content. 12 Academic Attire 13 Keynote Speakers Caps and Gowns 14–16 Keynote Speaker Profles Graduating seniors’ caps and gowns and master’s degrees’ caps and BACCALAUREATE DEGREES gowns are made of post-consumer 18 Honors recycled content; each cap and 19 Order of Ceremonies gown is made of a minimum of 20–21 College of Agriculture and Natural Resources 23 plastic bottles. 22 Residential College in the Arts and Humanities 23–24 College of Arts and Letters Recycle Your Cap and Gown 25–26 The Eli Broad College of Business Once all of your favorite photos are 27–29 College of Communication Arts and Sciences taken on campus, please recycle 30 College of Education your gown at the MSU Union 31–32 College of Engineering Spartan Spirit Shop.
    [Show full text]
  • H. Robert Horvitz
    WORMS, LIFE AND DEATH Nobel Lecture, December 8, 2002 by H. ROBERT HORVITZ Howard Hughes Medical Institute, McGovern Institute for Brain Research, Department of Biology, Massachusetts Institute of Technology, 77 Massachus- etts Ave., Cambridge, MA 02139, U.S.A. I never expected to spend most of my life studying worms. However, when it came time for me to choose an area for my postdoctoral research, I was in- trigued both with the problems of neurobiology and with the approaches of genetics. Having heard that a new “genetic organism” with a remarkably sim- ple nervous system was being explored by Sydney Brenner – the microscopic soil nematode Caenorhabditis elegans – I decided to join Sydney in his efforts. THE CELL LINEAGE After arriving at the Medical Research Council Laboratory of Molecular Biology (the “LMB”) in Cambridge, England, in November, 1974, I began my studies of C. elegans (Figure 1) as a collaboration with John Sulston. John, Figure 1. Caenorhabditis elegans adults. Hermaphrodite above, male below. John Sulston took these photographs, and I drew the diagrams. Bar, 20 microns. From (2). 320 Figur 2. John White. trained as an organic chemist, had become a Staff Scientist in Sydney’s group five years earlier. John’s aim was to use his chemistry background to analyze the neurochemistry of the nematode. By the time I arrived, John had turned his attention to the problem of cell lineage, the pattern of cell divisions and cell fates that occurs as a fertilized egg generates a complex multicellular or- ganism. John could place a newly hatched C. elegans larva on a glass micro- scope slide dabbed with a sample of the bacterium Escherichia coli (nematode food) and, using Nomarski differential interference contrast optics, observe individual cells within the living animal.
    [Show full text]
  • Table of Contents
    Umeå University Medical Dissertations New Series No 1080 • ISSN 0346-6612 • ISBN 978-91-7264-246-1 ___________________________________________________________________________ Protein Tyrosine Kinases and The Regulation of Signalling and Adhesion in Drosophila melanogaster Caroline Grabbe Umeå Centre for Molecular Pathogenesis Umeå University Umeå, Sweden, 2007 Copyright © 2007 by Caroline Grabbe ISBN 978-91-7264-246-1 _______________________________________________________ Printed in Sweden by Solfjädern Offset AB Umeå, 2007 2 To Chance, and Life Itself… (I det långa loppet träffar man bara det man siktat på. Så även om man missar sitt mål i första försöket så är det lika bra att sikta högt.) Henry David Thoreau 3 TABLE OF CONTENTS ABBREVIATIONS ................................................................................................................ 6 SUMMARY............................................................................................................................. 8 PAPERS INCLUDED IN THIS THESIS............................................................................. 9 PAPERS NOT INCLUDED IN THIS THESIS ................................................................... 9 INTRODUCTION................................................................................................................ 10 Drosophila melanogaster as a model system....................................................................... 10 Historical perspective............................................................................................................
    [Show full text]
  • Report 1978 Cold Spring Harbor Laboratory
    COLDLABORATORY SPRING HARBOR ANNUAL REPORT 1978 COLD SPRING HARBOR LABORATORY COLD SPRING HARBOR, NEW YORK Cover: Participants at 1978 Symposium (top to bottom) G. Selzer, F. Stahl, and J. Strathern; A. Kornberg, A. Falaschi, and R. Holliday; W. Arber and D. Nathans; W. Udry, A. Bukhari, and D. Baltimore Picture credits: Cover, 82, 90, 140, Ross Meurer; 14, Cindy Carpenter; 19, W. Udry; 11, 12,13, 17, 20, 67, 136, 142, 143, 153, Robert Yaffe COLD SPRING HARBOR LABORATORY COLD SPRING HARBOR, LONG ISLAND, NEW YORK OFFICERS OF THE CORPORATION Dr. Harry Eagle, Chairman Edward Pulling, Vice-Chairman Dr. Bayard Clarkson, Secretary Clarence E. Galston, Treasurer Robert L. Cummings, Assistant Treasurer William R. Udry, Administrative Director BOARD OF TRUSTEES Institutional Trustees Albert Einstein College of Medicine University of Wisconsin Dr. Harry Julian Davies Columbia University Wawepex Society Dr. Charles R. Cantor Bache Bleecker Duke University Dr. Walter Guild Individual Trustees Long Island Biological Association Emilio G. Collado Edward Pulling Robert L. Cummings Massachusetts Institute of Technology Roderick H. Cushman Dr. Herman Eisen Norris Darrell Memorial Sloan-Kettering Cancer Center Walter N. Frank, Jr. Dr. Bayard Clarkson Clarence E. Galston Mary Lindsay New York University Medical Center William S. Robertson Dr. Vittorio Defendi Mrs. Franz Schneider Princeton University Alexander C. Tomlinson Dr. Arnold J. Levine Dr. James D. Watson The Rockefeller University Dr. Rollin Hotchkiss Honorary trustees State University of New York Dr. H. Bentley Glass at Stony Brook Dr. Alexander Hollaender Dr. Joseph R. Kates Officers and trustees listed are as of December 31, 1978 DIRECTOR'S REPORT The collective decisions of knowledgeable men go sourone likes to advertise that we may have no meaningful more often than we want.
    [Show full text]
  • General Kofi A. Annan the United Nations United Nations Plaza
    MASSACHUSETTS INSTITUTE OF TECHNOLOGY DEPARTMENT OF PHYSICS CAMBRIDGE, MASSACHUSETTS O2 1 39 October 10, 1997 HENRY W. KENDALL ROOM 2.4-51 4 (617) 253-7584 JULIUS A. STRATTON PROFESSOR OF PHYSICS Secretary- General Kofi A. Annan The United Nations United Nations Plaza . ..\ U New York City NY Dear Mr. Secretary-General: I have received your letter of October 1 , which you sent to me and my fellow Nobel laureates, inquiring whetHeTrwould, from time to time, provide advice and ideas so as to aid your organization in becoming more effective and responsive in its global tasks. I am grateful to be asked to support you and the United Nations for the contributions you can make to resolving the problems that now face the world are great ones. I would be pleased to help in whatever ways that I can. ~~ I have been involved in many of the issues that you deal with for many years, both as Chairman of the Union of Concerne., Scientists and, more recently, as an advisor to the World Bank. On several occasions I have participated in or initiated activities that brought together numbers of Nobel laureates to lend their voices in support of important international changes. -* . I include several examples of such activities: copies of documents, stemming from the . r work, that set out our views. I initiated the World Bank and the Union of Concerned Scientists' examples but responded to President Clinton's Round Table initiative. Again, my appreciation for your request;' I look forward to opportunities to contribute usefully. Sincerely yours ; Henry; W.
    [Show full text]
  • What Is CRISPR? by Aparna Vidyasagar, Live Science Contributor | April 20, 2018 09:44Pm ET
    What Is CRISPR? By Aparna Vidyasagar, Live Science Contributor | April 20, 2018 09:44pm ET CRISPR technology is a simple yet powerful tool for editing genomes. It allows researchers to easily alter DNA sequences and modify gene function. Its many potential applications include correcting genetic defects, treating and preventing the spread of diseases and improving crops. However, its promise also raises ethical concerns. In popular usage, "CRISPR" (pronounced "crisper") is shorthand for "CRISPR-Cas9." CRISPRs are specialized stretches of DNA. The protein Cas9 (or "CRISPR-associated") is an enzyme that acts like a pair of molecular scissors, capable of cutting strands of DNA. CRISPR technology was adapted from the natural defense mechanisms of bacteria and archaea (the domain of single-celled microorganisms). These organisms use CRISPR-derived RNA and various Cas proteins, including Cas9, to foil attacks by viruses and other foreign bodies. They do so primarily by chopping up and destroying the DNA of a foreign invader. When these components are transferred into other, more complex, organisms, it allows for the manipulation of genes, or "editing." Until 2017, no one really knew what this process looked like. In a paper published Nov. 10, 2017, in the journal Nature Communications, a team of researchers led by Mikihiro Shibata of Kanazawa University and Hiroshi Nishimasu of the University of Tokyo showed what it looks like when a CRISPR is in action for the very first time. [A Breathtaking New GIF Shows CRISPR Chewing Up DNA] CRISPR-Cas9: The key players CRISPRs: "CRISPR" stands for "clusters of regularly interspaced short palindromic repeats." It is a specialized region of DNA with two distinct characteristics: the presence of nucleotide repeats and spacers.
    [Show full text]